MeSH term
Frequency | Condition_Probility | Animals | 8 | 0.0 |
Humans | 53 | 0.0 |
Adult | 16 | 0.0 |
Aged | 14 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Alleles | 4 | 0.0 |
Cell Cycle | 2 | 0.0 |
Codon | 2 | 0.0 |
DNA Mutational Analysis | 10 | 0.0 |
Esophageal Neoplasms/*genetics/metabolism | 2 | 14.0 |
Exons | 6 | 0.0 |
Gene Deletion | 6 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Homozygote | 7 | 0.0 |
Loss of Heterozygosity | 6 | 0.0 |
Middle Aged | 16 | 0.0 |
Models, Genetic | 2 | 0.0 |
Mutation | 10 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 47 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sulfites/pharmacology | 2 | 6.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Female | 18 | 0.0 |
*Gene Deletion | 9 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
*Cell Cycle Proteins | 17 | 1.0 |
Cell Division | 2 | 0.0 |
Enzyme Inhibitors | 4 | 4.0 |
*Genes, Tumor Suppressor | 7 | 0.0 |
Genotype | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Transfection | 2 | 0.0 |
Tumor Cells, Cultured | 17 | 0.0 |
Adolescent | 12 | 0.0 |
Child | 8 | 0.0 |
Child, Preschool | 8 | 0.0 |
*DNA Methylation | 8 | 1.0 |
*Genes, p16 | 6 | 6.0 |
Male | 18 | 0.0 |
Protein p16/*genetics/metabolism | 3 | 15.0 |
*Tumor Suppressor Proteins | 20 | 1.0 |
Base Sequence | 13 | 0.0 |
Cell Cycle Proteins/*genetics | 4 | 2.0 |
Introns | 2 | 0.0 |
Melanoma/*genetics | 6 | 4.0 |
Molecular Sequence Data | 14 | 0.0 |
*Mutation | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Protein p16/*genetics | 13 | 13.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Tumor Suppressor Proteins/*genetics | 2 | 1.0 |
Blotting, Northern | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
CpG Islands | 3 | 1.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Mice | 4 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
*Protein p16 | 2 | 5.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Chromosomes, Human, Pair 9/*genetics | 5 | 4.0 |
Genes, Tumor Suppressor | 4 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
Purine-Nucleoside Phosphorylase/genetics | 3 | 33.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Carrier Proteins/*genetics | 10 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Cyclins/*genetics | 2 | 1.0 |
*Enzyme Inhibitors | 3 | 7.0 |
Microsatellite Repeats | 4 | 0.0 |
Proteins/*genetics | 4 | 0.0 |
p14ARF Protein | 4 | 5.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Gene Expression | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
CpG Islands/genetics | 2 | 1.0 |
Disease Progression | 2 | 0.0 |
Esophageal Neoplasms/*genetics/pathology | 2 | 6.0 |
Blotting, Southern | 4 | 0.0 |
Genes, Tumor Suppressor/*genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Cell Line | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Survival Analysis | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Melanoma/genetics | 2 | 5.0 |
*Physical Chromosome Mapping | 2 | 1.0 |
Carrier Proteins/*genetics/metabolism | 4 | 1.0 |
Karyotyping | 2 | 0.0 |
Loss of Heterozygosity/genetics | 3 | 2.0 |
Rats | 2 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Genes, p16/*genetics | 3 | 6.0 |
Comparative Study | 6 | 0.0 |
Retinoblastoma Protein/*genetics | 2 | 4.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
DNA Methylation | 4 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Chromosomes, Human, Pair 9/genetics | 3 | 2.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
*Homozygote | 2 | 1.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Protein p16/genetics | 2 | 2.0 |
*Chromosome Deletion | 4 | 0.0 |
Purine-Nucleoside Phosphorylase/*genetics | 2 | 13.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Infant | 4 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
*Chromosomes, Human, Pair 9 | 8 | 3.0 |
Cyclin-Dependent Kinases/genetics | 2 | 3.0 |
Haplotypes | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Methylation | 2 | 0.0 |
Protein p16 | 8 | 5.0 |
*Point Mutation | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Genes, p53 | 2 | 0.0 |